Johnson & Johnson is trading at 3.13% up now at $279.69 after healthcare-sector strength.
- Healthcare stocks gained 1.37% during regular trading.
- No new September 2, 2026 company-specific catalyst was identified.
- Recent support includes FDA approval of IMAAVY for a rare blood disorder, announced August 24, 2026; the move appears primarily sector-driven rather than tied to fresh company news.